Home › Funds › 683 Capital Management, LLC › IOVA
683 Capital Management, LLC position in IOVA
IOVANCE BIOTHERAPEUTICS INC · Health Care
683 Capital Management, LLC reported holding 2,040,300 shares of IOVA (IOVANCE BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$30.2M, representing 1.34% of its reported portfolio and ranking #18 among its reported holdings. 683 Capital Management, LLC has disclosed IOVA holdings in 10 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How 683 Capital Management, LLC's IOVA position evolved
683 Capital Management, LLC first disclosed a stake in IOVA in Q3 2023 at 250,000 shares (US$1.1M). The position peaked in Q3 2026 at 2,040,300 shares, worth US$30.2M. Across 10 filings, 683 Capital Management, LLC increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,040,300 shares valued at US$30.2M — an increase of 1,396,000 shares quarter over quarter.. Notable position changes include a 600% increase in Q4 2023 (shares rose 82% over the following quarter), a 69% increase in Q1 2025 (shares fell 48% over the following quarter), a 217% increase in Q3 2026 (shares fell 48% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 250.00K | $1.14M | New |
| Q4 2023 | 1.75M | $14.23M | Add |
| Q1 2024 | 1.23M | $18.15M | Reduce |
| Q2 2024 | 1.50M | $12.03M | Add |
| Q3 2024 | 1.40M | $13.15M | Reduce |
| Q4 2024 | 1.42M | $10.48M | Add |
| Q1 2025 | 2.40M | $7.99M | Add |
| Q1 2026 | 644.30K | $2.26M | New |
| Q2 2026 | 644.30K | $2.68M | Hold |
| Q3 2026 | 2.04M | $30.24M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IOVA and 13F data
IOVA (IOVANCE BIOTHERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in IOVA — the largest reported positions include MHR FUND MANAGEMENT LLC (US$120.5M), Rhenman & Partners Asset Management AB (US$37.1M), Orion Investment Co (US$30.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IOVA
- MHR FUND MANAGEMENT LLC 28.97M sh · $120.50M · Q2 2026
- Rhenman & Partners Asset Management AB 2.50M sh · $37.09M · Q3 2026
- Orion Investment Co 2.08M sh · $30.88M · Q3 2026
- XCELSIOR ADVISOR PARTNERS LLC 1.84M sh · $27.29M · Q3 2026
- Palo Alto Investors LP 5.30M sh · $22.03M · Q2 2026
- C WorldWide Group Holding A/S 1.26M sh · $18.67M · Q3 2026
- Knott David M Jr 1.17M sh · $17.27M · Q3 2026
- Mirador Capital Partners LP 1.10M sh · $16.24M · Q3 2026
More on 683 Capital Management, LLC
FAQ
How long has 683 Capital Management, LLC held IOVA?
683 Capital Management, LLC has disclosed IOVA holdings in 10 of the last 13 reported quarters, going back to Q3 2023.
What is 683 Capital Management, LLC's current position in IOVA?
As of Q3 2026, 683 Capital Management, LLC holds 2.04M shares of IOVA (IOVANCE BIOTHERAPEUTICS INC), valued at $30.24M, representing 1.34% of its reported portfolio and ranking #18.
Has 683 Capital Management, LLC been buying or selling IOVA?
In the latest 13F filing (Q3 2026), 683 Capital Management, LLC increased its position in IOVA. The position peaked in Q3 2026 at 2.04M shares.
Which other funds hold IOVA?
Other major institutional holders of IOVA include MHR FUND MANAGEMENT LLC, Rhenman & Partners Asset Management AB, Orion Investment Co, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.